glucocorticoid-induced osteoporosis in patients with malignant lymphoma
Conditions
Interventions
Denosumab group: subcutaneous denosumab 60mg every 6 months and oral calcitriol 0.25ug daily for 1 year since before the start of chemotherapy
Alendronate group: oral alendronate 35mg once a week and
Sponsors
Toyama University Hospital Department of Hematology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with newly diagnosed malignant lymphoma Patients older than 65 years Patients who undergo chemotherapy with steroid such as R-CHOP and R-CHOP-like regimen Patients who signed the informed consent form
Exclusion criteria
Exclusion criteria: Patients with a history of hypersensitivity to any component of denosumab Patients with hypocalcemia Patients who are pregnant and who may be pregnant Patients with a condition that makes swallowing difficult such as stenosis and achalasia of esophagus Patients unable to sit upright or stand more than thirty minutes Patients with a history of hypersensitivity to bisphosphonates Patients with hypercalcemia or hypervitaminosis D Patients who are on osteoporotic treatment with denosumab or bisphosphonates Patients thought to be inappropriate for this study by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change of bone mineral density of the lumbar spine at 12 months after intervention | — |
Countries
Japan
Contacts
Public ContactTsutomu Sato
Toyama University Hospital Department of Hematology
Outcome results
None listed